Authorization

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics Inc (NASDAQ:IPSC) and Bristol Myers Squibb Co (NYSE:BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors.




The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform.




Bristol Myers Squibb has the option to add two additional programs.




Century will be responsible for development candidate discovery and preclinical development activities.




After that, Bristol Myers Squibb will be responsible for clinical development and commercialization subject to Century's co-promotion rights on certain programs.




Century will receive a $100 million upfront payment, and Bristol Myers Squibb will make a $50 million equity investment in Century Therapeutics' common stock at $23.14 per share.




In addition, Century will receive reimbursement of certain preclinical development costs and is eligible for additional milestone payments totaling more than $3 billion across the four potential programs.




Price Action: IPSC shares are up 17.10% at $15.48, and BMY stock is up 0.37% at $63.06 during the premarket session on the last check Monday.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Май 2022    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031